CLL patients treated with lenalidomide have a restored T-cell function, especially in terms of Th1-type cytokine release (IL-2, IFN-γ, TNF-α, IL-21), and formation of functional immune synapses (99, 155). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.